

HCR 3 STAFF MEASURE SUMMARY

Senate Committee On Rules

Prepared By: Leslie Porter, LPRO Analyst

Meeting Dates: 5/21

WHAT THE MEASURE DOES:

The measure recognizes and honors Dr. Brian Druker for his leadership and service to the people of the State of Oregon and the world.

Fiscal impact: No impact

Revenue impact: No impact

ISSUES DISCUSSED:

EFFECT OF AMENDMENT:

No amendment.

BACKGROUND:

Dr. Brian Druker was born on April 30, 1955, in Saint Paul, Minnesota. He developed a strong interest in the sciences as a child, gaining strong support from his parents, who emphasized the importance of higher education and community. In 1973, he graduated from Highland Park High School in Saint Paul, Minnesota. He graduated from the University of California, San Diego, with a Bachelor of Science degree in chemistry in 1977 and a Doctor of Medicine degree in 1981.

Brian Druker was inspired to become a physician-researcher after learning about breakthroughs for curing childhood leukemia. In 1984, he completed his internship and residency in internal medicine at Barnes Hospital of the Washington University School of Medicine and started a fellowship in medical oncology at the Dana-Farber Cancer Institute, eventually mentoring the next generation of leaders as an instructor at Harvard Medical School.

In 1993, Brian Druker started working at Oregon Health and Science University (OHSU), which welcomed and elevated his pioneering and cutting-edge research in oncology. Determined to prevent any further deaths from chronic myeloid leukemia, he focused on finding a first-of-its-kind cancer treatment that targets only cancer cells in the body. On May 10, 2001, the United States Food and Drug Administration approved his cancer-fighting drug Gleevec, which has saved hundreds of thousands of lives around the world in addition to jump-starting the era of precision cancer medicine.

In 2001, Brian Druker became the JELD-WEN Chair of Leukemia Research at OHSU. From 2002 to 2019, he was an investigator at the Howard Hughes Medical Institute, a nonprofit medical research organization. In 2007, he became director of the OHSU Knight Cancer Institute, leading the institute to international prominence for its ability to deliver personalized cancer medicine. In 2009, Brian Druker earned the Lasker-DeBaakey Award for Clinical Medical Research (known as the “American Nobel Prize”) for his revolutionary work in creating a magic bullet against cancer and providing hope to millions of patients and their loved ones.

In 2015, Brian Druker led one of the most ambitious fundraising efforts in Oregon history, the Knight Cancer Challenge, raising \$1 billion for the OHSU Knight Cancer Institute’s research from the Legislative Assembly, Phil and Penny Knight, and more than 10,000 donors around the world. In 2016, he launched the Cancer Early Detection Advanced Research Center, developing a large-scale early detection program with the world’s top scientists that built upon the scientific strengths of the OHSU Knight Cancer Institute. In 2017, Brian Druker led the OHSU Knight Cancer Institute in earning its designation by the National Cancer Institute as a Comprehensive

This summary has not been adopted or officially endorsed by action of the committee.

HCR 3 STAFF MEASURE SUMMARY

Cancer Center, making the institute one of the premier cancer research centers in the country, for its work in diagnosing, treating, and preventing cancer more effectively.

In 2019, in the presence of His Majesty the King of Sweden, Brian Druker was awarded the Sjöberg Prize by the Royal Swedish Academy of Sciences for his groundbreaking contributions to cancer research. Brian Druker has established himself as Oregon's best-known scientist and as a world-class leader in the fight against cancer, and he has developed a drug that has saved hundreds of thousands of lives.